Trials / Terminated
TerminatedNCT00954590
A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease
CONTACT: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Study of Dimebon in Patients With Moderate-to-Severe Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Medivation, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if Dimebon is safe and effective in patients with moderate to severe Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dimebon (latrepirdine) | 20 mg orally three times daily |
| DRUG | Placebo | Placebo orally three times daily |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-08-01
- First posted
- 2009-08-07
- Last updated
- 2016-09-27
Locations
2 sites across 2 countries: Chile, United Kingdom
Source: ClinicalTrials.gov record NCT00954590. Inclusion in this directory is not an endorsement.